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ABSTRACT
Objectives: Health decision-makers involved with coverage
and payment policies are increasingly developing policies that
seek information on “real-world” (RW) outcomes. Moti-
vated by these initiatives, the International Society for Phar-
macoeconomics and Outcomes Research (ISPOR) created a
Task Force on Real-World Data to develop a framework to
assist health-care decision-makers in dealing with RW data,
especially related to coverage and payment decisions.
Methods: Task Force cochairs were selected by the ISPOR
Board of Directors. Cochairs selected chairs for four working
groups on: clinical outcomes, economic outcomes, patient-
reported outcomes, and evidence hierarchies. Task Force
members included representatives from academia, the phar-
maceutical industry, and health insurers. The Task Force met
on several occasions, conducted frequent correspondence and
exchanges of drafts, and solicited comments on three drafts
from a core group of external reviewers and from the ISPOR
membership.
Results: We deﬁned RW data as data used for decision-
making that are not collected in conventional randomized
controlled trials (RCTs). We considered several characteriza-
tions: by type of outcome (clinical, economic, and patient-
reported), by hierarchies of evidence (which rank evidence
according to the strength of research design), and by type of
data source (supplementary data collection alongside RCTs,
large simple trials, patient registries, administrative claims
database, surveys, and medical records). Our report discusses
eight key issues: 1) the importance of RW data; 2) limitations
of RW data; 3) the fact that the level of evidence required
depends on the circumstance; 4) the need for good research
practices for collecting and reporting RW data; 5) the need
for good process in using RW data in coverage and reim-
bursement decisions; 6) the need to consider costs and ben-
eﬁts of data collection; 7) the ongoing need for modeling; and
8) the need for continued stakeholder dialogue on these
topics.
Conclusions: Real-world data are essential for sound cover-
age and reimbursement decisions. The types and applications
of such data are varied, and context matters greatly in deter-
mining the value of a particular type in any circumstance. It
is critical that policymakers recognize the beneﬁts, limita-
tions, and methodological challenges in using RW data, and
the need to consider carefully the costs and beneﬁts of differ-
ent forms of data collection in different situations.
Keywords: methodology, outcomes research, real-world
data, research design.
Why a Real-World DataTask Force?
Growing Use of Evidence Syntheses and
Outcomes Research
Health decision-makers involved with coverage and
payment policies are increasingly seeking information
on “real-world” (RW) outcomes on which to base their
decisions. Many of them are developing policies that
integrate evidence from different sources. These poli-
cies recognize the importance of evidence that goes
beyond information collected during clinical develop-
ment in randomized controlled trials (RCTs) required
by regulatory authorities for marketing approval. It is
broadly acknowledged that while RCTs provide a
“gold standard” in the sense that they provide solid
evidence of product efﬁcacy under carefully controlled
conditions, RCTs are carried out using selected popu-
lations under idealized conditions. In addition, they
are expensive to conduct. Other sources of data can
contribute in important ways to the evidence base
(e.g., demonstrating how a drug works in populations
or under conditions not studied in the trial, or relative
to another drug not included in the study).
Policy Developments
Recent policy initiatives highlight payers’ attempts to
collect and use such data. The Medicare Modernization
Act (MMA) of 2003 illustrates the US government’s
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attempt to bolster the evidence base on which private
health plans participating in the new Medicare drug
beneﬁt can base their coverage decisions. The MMA
contains a provision (Section 1013) calling on the
Agency for Healthcare Research and Quality (AHRQ)
to conduct research on the “outcomes, comparative
clinical effectiveness, and appropriateness of health
care, including prescription drugs” [1]. The AHRQ has
recently launched the Effective Health Care Program to
synthesize, generate, and translate knowledge to aid
stakeholders in grappling with the often difﬁcult deci-
sions they must make [2]. The AHRQ has also
announced that it is developing a “how-to” reference
guide to help health-care organizations in creating
patient registries to track the outcomes of medical
treatments, including drugs [3]. The US Centers for
Medicare and Medicaid Services (CMS) has also
recently issued a revised Coverage with Evidence Devel-
opment Guidance document that focuses on the need
for RW data to help inform national coverage decisions
for new technology [4]. Many private payers are adopt-
ing the Academy of Managed Care Pharmacy Format,
which calls for health plans to request formally that
drug companies present a standardized “dossier,” con-
taining detailed information not only on the drug’s
efﬁcacy and safety, but also on its projected effectiveness
and economic value relative to alternative therapies
[5,6].
Other efforts to review evidence systematically have
also gained momentum, including those by private and
public health plans. A notable initiative in the United
States is the Drug Effectiveness Review Project
(DERP), an alliance of 15 state Medicaid programs
and two nonproﬁt organizations, to synthesize and
judge clinical evidence for drug class reviews [7].
Around the globe, national reimbursement authorities
and the organizations that assist them, such as the
National Institute for Health and Clinical Excellence
(NICE), and the German Institut für Qualität und
Wirtschaftlichkeit im Gesundheitswesen (IQWiG), are
struggling with similar issues [8,9]. Both DERP and
IQWiG emphasize RCTs for clinical evidence as
opposed to synthetic modeling approaches, such as
those used by NICE to project RW effectiveness.
Task Force Objectives and Scope
Objectives
Motivated by the MMA and other efforts, and recog-
nizing the lack of a framework for considering RW
data in coverage and reimbursement decisions, the
International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) created a Task Force on
Real-World Data. The mission of the Task Force was
to develop a framework to assist health-care decision-
makers in dealing with RW data and information in
RW health-care decision-making, especially related to
coverage and payment decisions.
Scope
Deﬁning RW data. From the outset, the Task Force
grappled with the deﬁnition and appropriate charac-
terization of RW data. It seemed self-evident that RW
outcomes data should come from RW situations. Part
of the Task Force’s charge was to consider uses and
limitations of evidence not obtained from RCTs. On
the other hand, it was also clear that decision-making
is a highly integrative process of synthesizing informa-
tion from different sources—both “laboratory” and
real-world.
Some Task Force members questioned the appropri-
ateness of the term “RW data” in the ﬁrst place. In the
end, we decided to adhere to the term, not only
because it reﬂected the charge from the ISPOR Board,
but also because the term has gained currency in some
policy circles.
We settled on a deﬁnition that reﬂects data used for
decision-making that are not collected in conventional
RCTs. This is not to say that data from RCTs are
irrelevant or not used by decision-makers; indeed, they
remain the critical foundation for almost all initial
coverage and payment decisions. For if there is not a
belief in the plausibility of the underlying biological
mechanism or hypothesis, why should anyone seek
further evidence of effectiveness or cost impact in the
real world? Yet, efﬁcacy evidence in a particular group
or subgroup is typically insufﬁcient to project the size
of the effectiveness impact in the population that
would actually use a product. Decision-makers there-
fore seek additional types and sources of data.
Data versus evidence. Our Task Force also deliberated
distinctions between the terms “real-world data” and
“real-world evidence.” Some in our group favored the
latter term, or at least raised questions about whether
we meant evidence when we employed the term data.
The notion was that “data” conjures the idea of simple
factual information, whereas “evidence” connotes the
organization of the information to inform a conclusion
or judgment. Evidence is generated according to a
research plan and interpreted accordingly, whereas
data is but one component of the research plan. Evi-
dence is shaped, while data simply are raw materials
and alone are noninformative.
In the end, we adhered to the term “real-world
data” for reasons noted above. Nevertheless, we try to
remain sensitive to the distinctions throughout, and
emphasize that thorough knowledge of the quality of
the data source is necessary when deciding whether a
speciﬁc set of data can be used to answer a research
question or shed light on a decision.
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Focus on coverage and payment decisions. We focus
our report on coverage and payment (i.e., both pricing
and reimbursement) decisions. This sets it apart from
other contexts, such as direct patient care or regulatory
approval for marketing.
We recognize the tension that sometimes arises
between what is good for an individual patient and
what is good for the population at large. Evidence-
based medicine (EBM) has been deﬁned as “the con-
scientious, explicit and judicious use of current best
evidence in making decisions about the care of indi-
vidual patients” [10]. While physicians retain a pivotal
role in patient care decisions, other bodies such as
pharmacy and therapeutic (P&T) committees and
national reimbursement bodies (e.g., in Canada, Aus-
tralia, and most European countries) are taking on
greater importance in medical decision-making.
Drugs versus other interventions. While most of our
examples are drawn from the world of prescription
drugs, our report has implications for all types of
interventions, including drugs, devices, procedures,
and health programs.
US versus global focus. The motivation for the Task
Force came largely from the MMA and US policy
arena, but debates about types and sources of data are,
of course, present around the world—as suggested in
the different approaches taken, for example, by NICE
and IQWiG. Although many of our examples are taken
from US contexts, our ﬁndings are global in reach.
Task Force Participation
Task Force cochairs were selected by the ISPOR
Board of Directors. Cochairs selected chairs for four
working groups on: clinical outcomes, economic out-
comes, patient-reported outcomes (PROs), and evi-
dence hierarchies. The ﬁrst three groups correspond to
the three major areas of outcomes research that con-
tribute to the studies of comparative effectiveness and
economic evaluation sought by decision-makers. The
working group on evidence hierarchies addresses the
cross-cutting, foundational issue of the quality of evi-
dence. This paper reﬂects an integration of the various
working group reports.
Task Force members included representatives from
academia, the pharmaceutical industry, and health
insurance plans, and brought varied experiences in
using RW data. An outline and draft report developed
by the panel were presented at the 2005 International
and European ISPOR Meetings. The manuscript was
then submitted to a reference group of interested
ISPOR members for review and comment. The Task
Force met on several occasions, conducted frequent
correspondence and exchanges of drafts by electronic
mail, and solicited comments on three drafts from a
core group of external reviewers and more broadly
from the membership of ISPOR.
Types and Sources of RW Data
Characterizing RW Data
There are several ways in which one might characterize
RW data. One is by type of outcome: clinical, eco-
nomic, and patient-reported outcomes (the focus of
three of our working groups). An advantage of this
approach is that it corresponds to the way in which
many decision-makers conceive of data. A downside is
that it provides broad categories, each of which com-
bines many types and sources of evidence.
A second characterization involves traditional hier-
archies of evidence (the focus of our fourth working
group), which rank evidence according to the strength
of the research design. Typically, data from RCTs sit
atop the hierarchy followed by data from nonrandom-
ized intervention studies, followed by epidemiological
studies and so forth [11]. Evidence hierarchies provide
a useful ranking based on the rigor of the research
design; however, they do not provide a complete
picture of RW data. The results from many RCTs are
not generalizable to a broader population. Conversely,
a well-conducted observational study may prove
highly useful in certain situations provided that poten-
tial biases have been adequately addressed. Indeed,
some would argue that observational data can often
provide more relevant evidence regarding patient out-
comes in actual clinical practice than can a registration
RCT.
Finally, one might consider RW data by types of
data sources. The value of this classiﬁcation is that it
identiﬁes tangible sources of information. A potential
drawback is that it represents a simpliﬁcation that does
not capture important design issues within each source
of evidence.
Each of the three characterizations provides a dif-
ferent perspective on RW data. Collectively, we believe
they provide a useful portrait of the strengths, weak-
nesses, and complexities inherent in the topic.
Types of Outcomes
Clinical outcomes. Clinical outcomes include bio-
logical measures of morbidity (e.g., blood pressure,
cholesterol level, symptoms, and side effects) and mor-
tality. Clinical outcomes include both surrogate (inter-
mediate) and long-term measures. For purposes of this
discussion, we differentiate clinical outcomes from
health outcomes and especially PROs and health-
related quality of life (HRQoL).
Much of the data collected in phase III registration
trials involves clinical outcomes. Clinical outcome data
are also found in many other sources, such as patient
registries or observational databases. A key issue, dis-
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cussed in greater detail in Section 3.4, involves the
validity of clinical data from such sources.
Economic outcomes. “Economic outcomes” are nar-
rowly deﬁned here to include estimates of medical and
nonmedical resource utilization and their associated
costs. Such data are used to project the expected cost
of an intervention in the real world—e.g., in the
numerator of a cost-effectiveness ratio. As discussed
below, many sources of RW data are useful in provid-
ing use and cost information. Of course, we recognize
that the term economic outcomes can be more broadly
construed since economic evaluations consider both
beneﬁts and costs, but keep this narrow deﬁnition in
the interest of continuity with the original charter of
the Task Force.
Patient-reported outcomes/quality of life. Patient-
reported outcome is the term adopted by the Food and
Drug Administration (FDA) and internationally to
encompass any report coming directly from patients
about a health condition and its treatment, including
symptoms, functional status, HRQoL, treatment satis-
faction, preference, and adherence. Researchers have
long recognized that self-reports of outcomes related
to disease, injury, treatment or policy are important
because they provide the only direct voice that an
individual has in the health decision-making process.
This information has been widely used for decision-
making in the United States since the mid-1950s with
the establishment of the annual national health
surveys; other countries have subsequently developed
similar data collection mechanisms. The CMS adop-
tion of the Medicare Health Outcome Survey is recog-
nition of the importance of PRO data for under-
standing outcomes of the Medicare program. As
people live longer with chronic conditions, PROs have
become increasingly important to pharmaceutical
manufacturers in assessing the impact of emerging
chronic treatments and in communicating the beneﬁts
of these drug treatments in label and promotional
claims.
Interested parties have actively debated diverse con-
ceptual and methodological issues related to all types
of PROs, resulting in the publication of various “best
practices” documents [12,13]. The level of under-
standing of both the scientiﬁc rigor and its application
to the reporting of these subjective measures has
improved. Like any science, however, questions
remain. FDA and regulatory agencies globally have
recently developed statements to guide the develop-
ment and use of these measures, especially by the phar-
maceutical industry in the drug approval process
[14,15].
Evidence Hierarchies
Historically, evidence hierarchies have been linked to
“evidence-based medicine.” The thrust of the EBM
movement is to ground clinical practice in rigorous
research. EBM proponents emphasize that traditional
medical practice incorporated local practices and
expert opinion that were not tested in controlled
studies [11]. They stress the need for clinical research-
ers to document all study protocols, utilize appropriate
analytical techniques, and strive for internal consis-
tency [16]. Studies are to be considered externally valid
when ﬁndings are generalizable beyond local clinical
practices. A scientiﬁc body of evidence became reliable
and generalizable when similar results were reported
by different researchers across a range of study designs
and patient populations. For these reasons, RCTs were
placed at the top of the evidence hierarchy.
Decision-makers, however, quickly recognized the
impracticality of basing all of medicine on RCTs. For
one thing, RCTs are expensive. For another, even the
best RCT reﬂects a limited controlled experiment that
may not generalize to populations, settings, or condi-
tions not reﬂected in the trial. The need for non-RCT
information became apparent, raising the question of
how to grade information that by deﬁnition was of
“poorer quality.”
A number of groups have developed evidence hier-
archies over the years that reﬂect the primacy of data
from RCTs, and grade other types of evidence by the
rigor of the research design. For example, the hierar-
chy adopted by AHRQ grades evidence in order from
most to least rigorous as follows [17]: 1) systematic
reviews and meta-analyses of RCTs; 2) nonrandom-
ized intervention studies; 3) observational studies; 4)
nonexperimental studies; and 5) expert opinion.
The U.S. Preventive Services Task Force (USPSTF)
took the approach a step further recognizing that
decision-makers require information not only on the
rigor of the research design but also on the magnitude
of the net beneﬁt in support of a particular technology
or health service [18]. Recent work developed by the
Scottish Intercollegiate Guidelines Network and the
Oxford Center for Evidence-Based Medicine also rec-
ognized limitations of traditional grading systems [19].
Strict use of evidence hierarchies may not account for
the methodological quality of studies or may fail to
reﬂect the overall strength of the evidence base. Users
may misinterpret the grade of recommendation or they
may fail to properly weigh lower-grade recommenda-
tions [20]. Other groups maintain their own evidence
grading and classiﬁcation systems that combine judg-
ments about evidence quality with judgments about
the usefulness of the intervention [21].
Sources of RW Data
Real-world data can also be categorized by type of
data source. Our Task Force deﬁned six such sources:
1) supplements to traditional registration RCTs; 2)
large simple trials (also called practical clinical trials);
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3) registries; 4) administrative data; 5) health surveys;
and 6) electronic health records (EHRs) and medical
chart reviews.
Supplements to RCTs. To provide additional data
alongside standard clinically focused RCTs, research-
ers often gather information on variables such as
PROs, medical resource use, and costs. Such efforts
can add valuable evidence on treatment patterns for
common events, e.g., such as the doses of drugs used to
treat rejection in kidney transplantation [22].
Limitations to such data are also well-known: their
primary aim is to measure a key clinical efﬁcacy end
point in a carefully limited population and clinical
setting. Furthermore, trials are not usually powered
statistically to measure precisely the probability of rare
adverse or other events and hence are of limited use
in measuring the associated resource utilization and
costs. RCTs are generally conducted over a shorter
time frame than what is relevant for determining the
overall clinical and economic impact of an interven-
tion, and resource use is often protocol-driven.
Large simple trials. Large simple trials (also called
practical or pragmatic clinical trials) involve prospec-
tive, randomized assignment but aimed at larger more
diverse RW population [23]. Large simple trials have
the important strength of randomization, which mini-
mizes bias in the estimation of treatment effects. These
trials are by design larger than conventional RCTs. For
this reason, they are more likely to have sufﬁcient
power to capture signiﬁcant differences in key out-
comes of interest, such as hospitalizations.
Because the focus is on obtaining policy-relevant
outcomes, costs and cost-effectiveness are more likely
to be central end points, and the results can be more
readily generalized to the relevant treatment popula-
tion than those obtained from conventional RCTs:
costs are less likely to reﬂect protocol-driven health-
care use; well-documented variations in resource use
across various ethnic, racial, age groups, and sexes can
be better captured by opening the trial to a more
diverse population; people more at risk for adverse
events are less likely to be excluded from the trial, and
the related economic effects are more likely to be cap-
tured; and resource use and costs are more likely to
reﬂect those observed in community-based settings
where most people obtain their care, especially since
study drugs in phase III trials are generally provided
for free.
Nevertheless, the large size of a practical clinical
trial increases the cost of data collection and raises
some concerns about the quality of data collected.
Costs are increased not only because a larger number
of patients are enrolled, but also because a larger
number of settings are involved. Some of the issues
raised by economic data collection within practical
clinical trials are: identiﬁcation of where subjects
receive care may be more difﬁcult (less in a closed
system); data collection systems of community-based
settings may be less sophisticated than those of aca-
demic settings (e.g., more likely to use paper rather
than electronic records, thus increasing the likelihood
of data entry errors); there is more likely to be a lack of
standardization in ﬁnancial and billing systems across
different settings of care; and more study coordinators
will be involved in the data collection effort.
Registries. Registries are prospective, observational
cohort studies of patients who have a particular
disease and/or are receiving a particular treatment
or intervention. They can be used for understanding
natural history, assessing or monitoring RW safety and
effectiveness, assessing quality of care and provider
performance, and assessing cost-effectiveness [24].
Registries involve prospective data collection of
clinical, economic, and PRO information, and are
increasingly relying on real-time data capture. They
typically include a larger and more diverse group of
patients than what is generally studied in phase III
RCTs; therefore, they better reﬂect RW patients, man-
agement practices, and outcomes. Patients are often
followed over a longer time frame, allowing for an
assessment of longer-term outcomes. Most registries
have very few, if any, required visits, evaluations, or
procedures; therefore, the treatment patterns reﬂect
the everyday clinical decision-making that is most rel-
evant to providers and payers. Disease registries enable
providers and payers to gain insight into the most
cost-effective treatment approaches.
Because registries do not involve random assign-
ment to treatment, care must be taken in analyzing and
interpreting the results due to the inherent limitations
of observational studies. There is no guarantee that
patient groupings are comparable; therefore, registries
may not be suitable to test hypotheses, but are useful
to generate them. Furthermore, there are limitations in
terms of the amount of data that can be collected, and
because visit schedules are not required, data cannot
necessarily be obtained at ﬁxed intervals. Registries
sometimes include study sites that are not experienced
in conducting research, and without appropriate over-
sight, data integrity could be in question. Nevertheless,
the use of real-time data capture is likely to improve
data monitoring and integrity. Registries are, in some
cases, established to collect postmarketing safety data,
either in response to speciﬁc safety concerns or to fulﬁll
regulatory obligations established as a condition of
marketing approval.
Administrative data. Administrative data (typically
retrospective or real-time, if possible) are collected pri-
marily for reimbursement, but contain some clinical
diagnosis and procedure use with detailed information
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on charges. Claims databases lend themselves to retro-
spective longitudinal and cross-sectional analyses of
clinical and economic outcomes at patient, group, or
population levels. Such analyses can be performed at
low overall cost and in a short period of time. Given
the sheer size of claims databases, researchers can iden-
tify outcomes of patients with rare events more easily,
assess economic impact of various interventions, and
gain insight into possible association between interven-
tions and outcomes.
Administrative claims databases can prove very
useful in measuring resource use and costs, provided
some basic principles are met. A clear research ques-
tion needs to be deﬁned and addressed by an appro-
priate design from a well-deﬁned perspective. Available
statistical tools can be used to help control for some of
the potential biases. Methods and results should be
reported in a clear and transparent fashion, so that
other researchers are able to understand and reproduce
the analyses.
It is worth noting that with appropriate Institu-
tional Review Board (IRB) approvals and patient
consent, some health plan databases can be linked with
PROs, lab results, medical records, and physician
surveys—effectively becoming a blend of traditional
registries and claims data.
Beyond challenges posed by privacy issues, the
validity of retrospective claims database analyses
has been challenged on several fronts: data quality
(missing data, coding errors—whether random or
“intended”—and the lack of comprehensive data
across health-care settings); the lack of or very limited
clinical information on inpatient stays, health out-
comes, health status, and symptoms; limited valida-
tion; absence of a population denominator; and the
lack of distinction between costs and charges. Of
course, the large size of these databases may be able to
overcome the issue of missing data if they are missing
at random. If data quality can be ascertained and
privacy issues addressed, then treatment selection bias
in the sample is the most common and challenging
methodological issue. Estimates of the effects and costs
can be biased because of a correlation between unob-
served factors associated with treatment selection and
outcomes, such as baseline health status.
Health surveys. Health surveys are designed to collect
descriptions of health status and well-being, health-
care utilization, treatment patterns, and health-care
expenditures from patients, providers, or individuals
in the general population. Health surveys typically
collect information on representative individuals in
the target population, whether patients, physicians or
general population, and are methodologically rigor-
ous, for example, relying on complex sample survey
designs. With these designs, surveys can provide infor-
mation about all members of the target population,
not just those who are participating in a given RCT, or
members of a particular health plan. As a result, health
survey data can make unique contributions about gen-
eralizability of treatments and their impacts and about
use of and expenditures for health services.
The major limitation of health survey data for
initial coverage and reimbursement decisions is the
lack on relevant data on speciﬁc products. Survey data
are also subject to issues of subjectivity and recall bias.
Electronic health records and medical chart review.
Finally, we note that EHRs (and other technologies
capturing real-time clinical treatment and outcomes)
are important sources for RW data for a wide range
of clinical settings throughout the world. The expan-
sion of electronic data capture is essentially lowering
the cost of the medical chart reviews that have been
widely used in the past to produce speciﬁc informa-
tion on the RW use of speciﬁc tests or drugs for
particular conditions. EHRs—such as the UK General
Practice Research Database—contain more detailed,
longitudinal information including disease-speciﬁc
symptoms at the personal level and should greatly
expand the use of this type of information. Neverthe-
less, transforming the information for research pur-
poses requires high-end statistical analysis tools and
remains a challenge.
Key Findings
Recognizing the Importance of RW Data
We conclude with a strong afﬁrmation of the need for
RW data. As we have emphasized, RCTs have many
advantages: their prospective design, prespeciﬁed well-
deﬁned end points, randomization and control groups,
and blinding all work to provide unbiased measures of
impact in the trial population; however, this strong
internal validity can limit their external validity and
generalizability about which interventions work best
when implemented in different settings.
Decision-makers rely on multiple sources of RW
data that must be integrated or synthesized in some
fashion. While RCTs remain the gold standard for
demonstrating clinical efﬁcacy in restricted trial set-
tings, other designs contribute to the evidence base. In
some situations, RW data may provide clear advantage
for understanding outcomes of treatment, for example,
for patients excluded from trials, patients in actual
clinical practice settings (vs. research settings), and
patients whose treatment is not determined by trial
protocol or practice guidelines.
Among the beneﬁts of RW data is that they can
provide:
• Estimates of effectiveness rather than efﬁcacy in a
variety of typical practice settings;
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• Comparison of multiple alternative interventions
(e.g., older vs. newer drugs) or clinical strategies to
inform optimal therapy choices beyond placebo
comparators;
• Estimates of the evolving risk–beneﬁt proﬁle of a
new intervention, including long-term (and rare)
clinical beneﬁts and harms;
• Examination of clinical outcomes in a diverse
study population that reﬂects the range and distri-
bution of patients observed in clinical practice;
• Results on a broader range of outcomes (e.g.,
PROs, HRQoL, and symptoms) than have tradi-
tionally been collected in RCTs (i.e., major mor-
bidity and short-term mortality);
• Data on resource use for the costing of health-care
services and economic evaluation;
• Information on how a product is dosed and
applied in clinical practice and on levels of com-
pliance and adherence to therapy;
• Data in situations where it is not possible to
conduct an RCT (e.g., narcotic abuse);
• Substantiation of data collected in more con-
trolled settings;
• Data in circumstances where there is an urgency
to provide reimbursement for some therapies
because it is the only therapy available and may be
life-saving;
• Interim evidence—in the absence of RCT
data—upon which preliminary decisions can be
made; and
• Data on the net clinical, economic, and PRO
impacts following implementation of coverage or
payment policies or other health management
programs (e.g., the kind of data CMS expects to
collect under its coverage with evidence develop-
ment policy) [25].
Recognizing the Limitations of RW Data
We also recognize important limitations of RW data.
For all nonrandomized data, the most signiﬁcant
concern is the potential for bias. Retrospective or pro-
spective observational or database studies do not meet
the methodological rigor of RCTs, despite the avail-
ability of sophisticated statistical approaches to adjust
for selection bias in observational data (covariate
adjustment, propensity scores, instrumental variables,
etc.). Observational studies need to be evaluated rig-
orously to identify sources of bias and confounding,
and adjusted for these before estimating the impact
of interventions on health outcomes. Observational
or database studies may also require substantial
resources.
The Level of Evidence Required Depends on
the Circumstance
The complexity of data collection underscores the fact
that the level of evidence required in any circumstance
will relate to the question at hand. It is important to
recognize the variable quality of all data (whether pro-
spective or retrospective, or experimental or observa-
tional). The extent to which data provide good or bad
evidence depends on the research design, the quality of
the information collected, and how the data are used.
The optimal solution will depend on the circum-
stances. Decisions typically rely on multiple sources,
and are best thought of as conditional—to be revisited
as additional evidence is generated.
Ongoing work in evidence hierarchies recognizes
this complexity. As noted, new approaches for grading
evidence depend on the quality of the evidence and the
magnitude of the net beneﬁt. The approaches are more
explicit about which studies provide stronger evidence
in support of the use of a particular health service or
drug.
In all likelihood, we need clinical trials that are
more practical and “RW data” that are more statisti-
cally rigorous from a design and analysis standpoint
[26]. For the collection of economic data alongside
RCTs, this suggests that data collection efforts focus
on “big ticket” items, rather then trying to capture a
complete picture of resource use. To ensure that the
data collected in these trials are of high quality, a
greater emphasis is needed on centralized training of
study coordinators and records abstractors and on the
centralized quality control mechanisms.
The high cost associated with data collection may
further necessitate linkage of trial data to claims data,
which requires collection of sensitive patient identiﬁers
such as Social Security numbers. This may raise addi-
tional patient conﬁdentiality concerns with Institu-
tional Review Boards and may require collaboration
and cooperation of a government agency, or private
insurers to ensure patient-level claims can be made
available.
The Need for Good Research Practices for Collecting
and Reporting RW Data
Our review underscores the need for good practices for
collecting and reporting RW data. In terms of data
collection, it is important that efforts follow well-
established research practices. These include posing
well-deﬁned questions, specifying time frames for the
duration of data collection, conducting periodic moni-
toring to ensure quality and responsiveness to research
questions, and limiting sample sizes to the minimum
necessary. These good practices should also ensure that
informed consent and human subject protections are in
place.
Registries, for example, should be carefully
planned, beginning with clear and achievable objec-
tives and extensive clinical input. A protocol or study
plan should guide the conduct of the registry and the
data analysis. Data collection tools should be carefully
designed and tested, and site coordinators thoroughly
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trained to ensure data quality. Quality control mecha-
nisms should be in place to identify and resolve study
issues. There is also a need to balance research needs
with privacy concerns as it becomes easier to link data
across multiple sources.
Researchers should draw inferences from observa-
tional data with caution. For example, a widely recog-
nized challenge with the analysis of RW data is the
need to correct for sample selection bias—deﬁned as
the bias introduced by unobserved variables that are
correlated with both treatment selection and patient
outcomes (e.g., unobserved illness severity). On the
other hand, it is less well-recognized that selection bias
is just one of a variety of factors including missing
variables, measurement error, incorrect functional
form and two-way causation (“structural simultane-
ity”) that can introduce bias into treatment estimates.
All of these problems have the common statistical
result of introducing a correlation between the treat-
ment variable and the error term, which is the source
of the bias. Overcoming this “endogeneity bias” is the
most common and vexing challenge that arises in the
analysis of RW data. Statistical tests for endogeneity
bias exist, along with methods for its correction
although operationalizing these methods is often a sig-
niﬁcant challenge: in many circumstances, our ability
to minimize this bias is limited by the lack of exog-
enous variation in the available data [27,28].
Good Process in Using RW Data in Coverage and
Reimbursement Decisions
We also recognize the importance of the processes
implemented by decision-makers in using RW data
in coverage and reimbursement. Observers point to
several conditions for establishing good process,
including transparency (the decision and the rationale
for making them must be publicly accessible) and rel-
evance (there must be a reasonable explanation for a
decision’s rationale) [29]. They should also be fair in
the sense that RW data will be used in similar fashion
across technologies, or if situations demand a different
rationale, the circumstances or principles would be
known. Decisions should not be “bureaucratically
arbitrary,” or based on reasons that people do not view
as meaningful or just.
Typically, the amount of RW data available for the
initial coverage and reimbursement decision is very
limited: instead, effectiveness projections are modeled
from efﬁcacy data. Good process would encourage the
subsequent gathering of RW data, in part by updating
coverage and reimbursement decisions based on those
data.
Processes should also allow opportunity for stake-
holder participation. Different stakeholders (physi-
cians, patients, family caregivers, payers, hospitals,
regulatory agencies, employers, manufacturers, and
researchers) may have different perspectives on the use
and value of RW data. Ideally, there will be a mecha-
nism for challenge and change, which contributes to
democratic governance.
The Need to Consider the Costs and Beneﬁts of
Data Collection
Two critical questions are how much RW data should
be collected and who should pay for it. Evidence costs
money. Inevitably, there are questions about whether
resources devoted to the endeavor are worthwhile.
There is a need to prioritize decisions about RW data
such that the beneﬁts of collecting additional informa-
tion are expected to outweigh the costs.
The tool of “value-of-information (VOI) analysis”
offers a formal approach to deciding when and what
types of data to collect. Formal use of decision analysis
and VOI analysis can help determine whether an inter-
vention should be adopted, whether additional evi-
dence to further inform that decision is worth
gathering, and what kind of information is of greatest
value [30].
The VOI analysis evaluates the extent to which new
evidence might improve expected beneﬁts by reducing
the chance for error, and compares that improvement
to the cost of the information. Evidentiary consider-
ations will depend on the particular circumstances of a
decision (the consequences of an error, what can be
learned from additional evidence, how new knowledge
will change and improve the option identiﬁed as
optimal), rather than on predetermined speciﬁcations
about the type of study design (e.g., RCT). Explicit
consideration is given to the potential positive health
outcomes forgone due to delays in coverage as well as
the potential adverse consequences of too rapid uptake
when the risk–beneﬁt ratio is highly uncertain.
The Need for Modeling
A previous ISPOR Task Force on modeling studies
emphasized that the purpose of modeling is to “struc-
ture evidence on clinical and economic outcomes in a
form that can help inform decisions” [31]. They stated:
“Models synthesize evidence on health consequences
and costs from many different sources, including data
from clinical trials, observational studies, insurance
claim databases, case registries, public health statistics,
and preference surveys.”
Our ﬁeld has adopted bioclinical cost-effectiveness
models as an integrative framework, incorporating
biological, clinical outcomes, and economic data into
a decision-making structure. Within this general
structure, there are several different types of possible
pharmacoeconomic evaluations, such as cost–
consequences, cost–utility, and cost–beneﬁt analyses.
Such models and analyses are the primary vehicle for
combining RCT and RW data to support coverage and
reimbursement decision-making. At the same time,
expanded use of RW data in assessing postlaunch cost-
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effectiveness is needed to update the modeling pro-
jections made to support initial coverage and
reimbursement decisions.
In terms of good research practice, the previous
Task Force emphasized the need for transparency of
assumptions, including the point that “conclusions are
conditional upon the assumptions and data on which
the model is built.”
The Need for Ongoing Dialog
Finally, our review highlights the need for ongoing
stakeholder dialog on all of these issues. Implicit in
much of our discussion is a central policy question
about the appropriate role of the public sector in pro-
ducing and judging evidence. Who collects and evalu-
ates RW data, which pays for these efforts, and what
magnitude of resources is provided are key questions
for policymakers worldwide. There is no general regu-
latory requirement for collecting RW data.
In the United States, CMS has called for data that
reﬂect RW practice. In addition, FDA is requiring the
implementation of mandatory registries in instances
where there is any concern regarding long-term safety
of a therapy. The opportunity for funding observa-
tional studies of therapy is limited compared with tra-
ditional epidemiological studies and therapeutic trials.
It is critical that we have an intelligent and vigorous
public discussion on these and other issues.
Conclusions
Real-world data are essential for sound coverage,
payment, and reimbursement decisions. The types and
applications of such are varied, and context matters
greatly in determining the value of a particular type of
evidence in any circumstance. Different study designs
can provide useful information in different situations.
RCTs remain the gold standard for demonstrating
clinical efﬁcacy in restricted trial setting, but other
designs—such as observational registries, claims data-
bases, and practical clinical trials—can contribute to
the evidence base needed for coverage and payment
decisions.
It is critical that policymakers recognize the beneﬁts,
limitations, andmethodological challenges in using RW
data, and the need to carefully consider the costs and
beneﬁts of different forms of data collection in different
situations. In this report, we have attempted to identify
the salient issues in developing and using RW data. We
acknowledge many challenges ahead and view this
effort as a starting point for future debates.
Postscript
Prior to ﬁnalizing this report, we reviewed more
than 70 comments from ISPOR members on our
draft report, which are accessible at the ISPOR web-
site at http://www.ispor.org/workpaper/RWD_TF/
MemberComments.pdf. One recurring theme was a
perceived need for more guidance on precisely how
decision-makers will actually use RW data after the
launch of a product. Other themes included calls for
more discussion of limitations of various aspects of
RW data collection, calls for more attention to the uses
of EHRs, and comments that our report could have
used more emphasis on international data collection
and on medical devices. Although we made numerous
changes to this document in light of these comments,
we still refer the interested reader to the comments on
the ISPOR website, as several of the important broader
themes and limitations they raise should help to deﬁne
the agenda for the next steps in this continuing inquiry.
The members of the Task Force Working Groups contributed
signiﬁcantly to the preparation of this report: Evidence Hier-
archies: Joe Jackson, Phil Sarocco, Jennifer Elston-Lafata;
Clinical Outcomes: Marc Berger, Bruce Carleton, Gurvaneet
Randhawa, Anne Smith; Economic Outcomes: Bill Crown,
Jens Grueger, Penny Mohr, Les Noe; Patient-Reported Out-
comes: Jamie Banks, Rick Chapman, Mary Cifaldi, Andreas
Pleil. The Task Force is grateful to Marilyn Dix Smith, and
Erin Gilli of ISPOR for administrative support. The views
expressed reﬂect those of Task Force members and do not
necessarily reﬂect the views of the broader ISPOR members,
nor their employers.
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